Friday 6 November 2026
Export ENOV’s income statement to Excel — free account
Enovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- +100.6%
- Free cash flow
- +20.3%
- Total debt
- −7.45%
Quarter to September 2026, against a year earlier
27.07
1.55
−5.42%
Follow ENOV
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 4 | 5 |
| (58.40%) | (55.48%) | (54.27%) | (29.97%) | ||
| (27.69%) | (26.12%) | (25.07%) | (12.91%) | ||
ROIC |
(25.53%) | (24.14%) | (23.55%) | (10.83%) | |
Return on Tangible Assets |
(106.17%) | (98.83%) | (97.48%) | (44.17%) | |
Average Days of Receivables |
71.89 | 71.16 | 70.22 | 67.78 | |
Free Cash Flow per Share |
0.35 | 0.63 | 1.11 | 1.19 | |
Free Cash Flow |
19.92 | 35.92 | 63.66 | 69.56 | |
Capital Expenditures |
(197.38) | (206.92) | (206.44) | (189.46) | |
| Other line items | |||||
Cash ROIC |
0.71% | 1.27% | 2.29% | 2.51% | |
Accounts Receivable Turnover |
5.29 | 5.18 | 5.13 | 5.36 | |
Accounts Payable Turnover |
4.92 | 4.48 | 4.40 | 4.47 | |
Inventory Turnover |
1.60 | 1.51 | 1.45 | 1.45 | |
Average Days of Payables |
75.82 | 86.65 | 79.44 | 81.98 | |
Days of Inventory on Hand |
236.27 | 244.41 | 245.77 | 253.65 | |
Tax Rate |
0.02 | 0.03 | 0.03 | 0.05 | |
Research and Development Expense of Revenue |
5.35% | 5.41% | 5.41% | 5.46% | |
Selling, General and Administrative Expense of Revenue |
47.60% | 47.58% | 47.05% | 46.67% | |
Share Based Compensation of Revenue |
1.46% | 1.50% | 1.51% | 1.46% | |
Interest Coverage |
(32.28) | (30.77) | (30.90) | (14.69) | |
Operating CF/Net income |
(0.18) | (0.21) | (0.25) | (0.49) | |
Depreciation/Fixed assets |
2.65 | 2.59 | 2.55 | 0.00 | |
Capex/Depreciation |
(0.15) | (0.15) | (0.15) | 0.00 | |
Revenue per Share |
39.39 | 39.75 | 39.87 | 39.43 | |
Operating CF per Share |
3.81 | 4.24 | 4.69 | 4.43 | |
Capex per Share |
(3.46) | (3.61) | (3.58) | (3.24) | |
Capex to Sales |
0.09 | 0.09 | 0.09 | 0.08 |
Columns are period end dates · fundamentals updated 5 Nov 2026